Why the study?
Does verapamil, nicardipine, or nitroglycerin reduce infarct size and arrhythmias in an in vivo rabbit model of ischemia/reperfusion?
Does verapamil, nicardipine, or nitroglycerin reduce infarct size and arrhythmias in an in vivo rabbit model of ischemia/reperfusion?
Verapamil and nitroglycerin afford significant protection against myocardial ischemia and reperfusion injury in a rabbit model.
Does not support clinical use in myocardial infarction; leaves open translation of rabbit findings to human reperfusion injury.
The aim of this experiment was to establish whether verapamil, nicardipine, and nitroglycerin have (1) infarct size-limiting effects and (2) antiarrhythmic effects in in vivo rabbit hearts during ischemia/reperfusion. Rabbits received regional ischemia by 30 min of left anterior descending coronary artery occlusion followed by 3 hours of reperfusion under ketamine and xylazine anesthesia. The animals were randomly assigned to the following 4 treatment groups: a control group, a verapamil group, a nicardipine group, and a nitroglycerin group. A continuous infusion of verapamil, nicardipine, or nitroglycerin was initiated 5 min prior to ischemia. Infarct size/area at risk decreased in verapamil, and nitroglycerin. The incidence of ischemia-induced arrhythmia decreased in nicardipine, verapamil and nitroglycerin. The incidence of reperfusion-induced arrhythmias decreased in verapamil and nitroglycerin. From the present experimental results, verapamil and nitroglycerin rather than nicardipine did afford significant protection to the heart subjected to ischemia and reperfusion in a rabbit model.
No takes yet. Share an insight, caveat, or question.
Yui et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: